Cingulate (CING) vs Gain Therapeutics (GANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cingulate (CING) has outperformed Gain Therapeutics (GANX) over the past year, gaining 15.9% versus a loss of 22.0%. Cingulate is the larger company by market cap ($71.0 million vs $70.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | GANX |
|---|---|---|
| Share price | $4.88 | $1.62 |
| Market cap | $70.96M | $70.48M |
| 1-day change | +0.21% | -3.29% |
| YTD return | +12.44% | -49.84% |
| 1-year return | +15.91% | -21.98% |
| 5-year return | — | -76.73% |
| EPS (TTM) | $-3.51 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.89 | $4.34 |
| 52-week low | $3.16 | $1.53 |
| Distance from 52-week high | -58.96% | -62.79% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +334.43% | +345.82% |
| Average volume | 139.16K | 493.98K |
| Shares outstanding | 14.54M | 43.64M |
| Employees | 14 | 20 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed GANX by 37.9 percentage points over the past year.
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Healthcare · Biotechnology · 14 employees
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Healthcare · Biotechnology · 20 employees
CING vs GANX FAQ
Which is bigger, Cingulate or Gain Therapeutics?
Cingulate (CING) is larger, with a market capitalization of $70.96M compared with $70.48M for Gain Therapeutics (GANX).
Which stock has performed better over the past year, CING or GANX?
CING returned +15.91% over the past 12 months, compared with -21.98% for GANX (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and Gain Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.